SEP 4·SEC EDGARLow
Rosenthal Arnon sold $193K of ALEC
Rosenthal Arnon (Chief Executive Officer) sold 72,606 shares of Alector, Inc. (ALEC) at $2.66 ($0.19M total) on 2026-09-03.
StockNASDAQ · US · USDHealthcare · Biotechnology
$ALEC
Alector, Inc.
Price · $ALECvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $ALEC in the last 7 days.
Insider · 30dAll trades →
- Buys
- — 0 txs
- Sells
- $296K 5 txs
Wong-Sarad Grace3× · $25K
10b5-1 share of filings40%
Top stories · $ALECMore →
AUG 6·SEC EDGAR 8-K
Alector, Inc. (ALEC): Results of Operations and Financial Condition
Alector, Inc. (ALEC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Alector Reports Second Quarter 2026 Financial Results and Provides Business Update Advancing the Alector Brain Carrier (ABC) blood-brain barrier platform across antibodies, enzymes, and siRNA, with AL137 advancing as Alector’s lead ABC-enabled anti-amyloid beta (Aβ)
JUL 10·benzinga.com
GSK Adds Positive Phase 3 Lung Cancer Data, Ends Alector Partnership - GSK (NYSE:GSK)
GSK said its Ris-Rez Phase 3 lung cancer trial in China showed statistically significant overall survival and progression-free survival gains versus topotecan, with no new safety signals. GSK plans a China regulatory submission and has exclusive rights outside parts of China. The article also says Alector repaid $10.43M and ended its collaboration with GSK.
ALEC sentiment & insider activity
Recent ALEC coverage spans insider activity, corporate actions and earnings.
In the last 30 days, ALEC insiders filed 5 SEC Form 4 transactions — no purchases and 5 sales ($296K). The most active reporter was Wong-Sarad Grace, Principal Accounting Officer, with 3 filings. 40% of those filings were made under pre-arranged Rule 10b5-1 plans.
What's driving ALEC
The insider sale may signal short-term confidence concerns, potentially pressuring the stock.
The filing updates runway and provides concrete IND timing targets for its lead ABC program, which can shift biotech risk pricing.
GSK said its Ris-Rez Phase 3 lung cancer trial in China showed statistically significant overall survival and progression-free survival gains versus topotecan, with no new safety signals. GSK plans a China regulatory submission and has exclusive rights outside parts of China. The article also says Alector repaid $10.43M and ended its collaboration with GSK.
Termination of the GSK collaboration and associated debt repayment are credit and pipeline-risk negatives, but the cash outflow is capped by the disclosed payoff amount.
This is routine corporate governance disclosure with no new financial guidance or material transaction terms.
alphai scores every news story that mentions ALEC with an AI model for sentiment and relevance, and aggregates insider trades from Alector, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $ALEC
Score
Rosenthal Arnon sold $193K of ALEC
Rosenthal Arnon (Chief Executive Officer) sold 72,606 shares of Alector, Inc. (ALEC) at $2.66 ($0.19M total) on 2026-09-03.
1 min readAlector, Inc. (ALEC): Results of Operations and Financial Condition
Alector, Inc. (ALEC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Alector Reports Second Quarter 2026 Financial Results and Provides Business Update Advancing the Alector Brain Carrier (ABC) blood-brain barrier platform across antibodies, enzymes, and siRNA, with AL137 advancing as Alector’s lead ABC-enabled anti-amyloid beta (Aβ)
6 min read
GSK Adds Positive Phase 3 Lung Cancer Data, Ends Alector Partnership - GSK (NYSE:GSK)
GSK said its Ris-Rez Phase 3 lung cancer trial in China showed statistically significant overall survival and progression-free survival gains versus topotecan, with no new safety signals. GSK plans a China regulatory submission and has exclusive rights outside parts of China. The article also says Alector repaid $10.43M and ended its collaboration with GSK.
4 min readAlector, Inc. (ALEC): Termination of a Material Definitive Agreement
Alector, Inc. (ALEC) filed an SEC Form 8-K — Termination of a Material Definitive Agreement. 8-K false 0001653087 0001653087 2026-07-06 2026-07-06 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 06,
4 min readAlector, Inc. (ALEC): Submission of Matters to a Vote of Security Holders
Alector, Inc. (ALEC) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001653087 0001653087 2026-06-17 2026-06-17 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17,
2 min read
UAE Business: ALEC unit Target wins $500m three EPC contracts in Gulf
ALEC Holdings said its subsidiary Target Engineering Construction Company – SP won three Gulf EPC contracts totaling over $500 million, according to a filing to the Dubai Stock Market. The projects have execution periods of 10, 21 and 36 months. ALEC said the awards’ financial impact will be recognized over those periods under its revenue policy, and it did not name clients, locations or scope.
3 min readRosenthal Arnon sold $172K of ALEC
Rosenthal Arnon (Chief Executive Officer) sold 87,216 shares of Alector, Inc. (ALEC) at $1.97 ($0.17M total) on 2026-06-02.
2 min readWong-Sarad Grace sold $7K of ALEC
Wong-Sarad Grace (Principal Accounting Officer) sold 3,475 shares of Alector, Inc. (ALEC) at $1.88 on 2026-06-03 under a Rule 10b5-1 trading plan.
2 min readWong-Sarad Grace sold $11K of ALEC
Wong-Sarad Grace (Principal Accounting Officer) sold 5,709 shares of Alector, Inc. (ALEC) at $1.97 on 2026-06-02.
2 min readBerkley Neil Lindsay sold $38K of ALEC
Berkley Neil Lindsay (CFO & Chief Business Officer) sold 19,360 shares of Alector, Inc. (ALEC) at $1.97 on 2026-06-02.
2 min read